A 24 week, double blind, randomized study to investigate the effect of 500 microg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstructive pulmonary disease.
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms HERO
- 04 May 2012 Additional lead trial investigator (D. Bredenbroker) identified as reported by ClinicalTrials.gov.
- 04 May 2012 Company added to the associations field as reported by ClinicalTrials.gov record.
- 25 Jan 2012 Additional trial identifier (NCT00108823) identified as reported by ClinicalTrials.gov.